HNRNPDL

Across TCGA pan-cancer cohorts, HNRNPDL Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated HNRNPDL data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher HNRNPDL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HNRNPDL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, LUSC, and HNSC are the cancer types where HNRNPDL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
LUSC	DFS	Median	All	0.151	0.750	<.001	36	view →
HNSC	DFS	Median	II,III,IV	0.128	0.695	.002	18	view →
ESCA	OS	Median	II,III,IV	0.319	0.707	.014	12	view →
STAD	OS	Median	All	0.250	0.729	.028	12	view →
SCLC	OS	Median	III,IV	0.082	0.630	.001	6	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →
UCEC	DFS	Median	II,III,IV	1.000	0.446	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

HNRNPDL–ACC (DFS)

Open the ACC breakdown →